EFFECTS OF THE IMMUNOMODULATOR ‘GALAVIT’ ON THE DEVELOPMENT OF B16 MELANOMA IN MICE

Abstract

In recent years, major attention has been devoted to immunotherapy in oncology. Immunotherapy is a promising treatment approach targeted to inhibit tumor growth via stimulating the body’s antitumor immune response. Purpose. The study was aimed to investigate the relationship between melanoma growth and metastasis in mice with the various schemes of Galavit treatment. Materials and methods. We used B16-F10 melanoma in F1-mouse as an experimental model. We divided animals in 3 groups: control (no therapy after tumor transplantation); immediate Galavit therapy at a dose of 5 mg/mouse after tumor transplantation; postponed Galavit therapy a week after tumor transplantation at doses of 5mg/mouse. We evaluated the rate of tumor node growth, 50-day survival rate and metastatic development after the 50th day follow-up period. Results. We revealed 80% survival rate for 50-day observation period in the control group. Interestingly, the 50-day survival rate was 60% for the animals treated with Galavit immediately after tumor inoculation. In other group with postponed Galavit therapy, survival rate was 100 %. A similar pattern was observed for tumor growth rates. Conclusion. We found that therapy with Galavit a week after tumor inoculation significantly increased the 50-day survival rate, suppressed tumor growth and the development of metastases in comparison with the control group and the group with immediate Galavit administration.

Keywords

• f1-mouse
• b16-f10 melanoma
• immunomodulatory
• galavit
• macrophages
• survival rate
• metastases